Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
55
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
News
California Launches First State-Branded Insulin Program, Offering $55 Five-Pack to Combat High Drug Costs
California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025.
Virginia Approves Incentive Packages for AstraZeneca and Eli Lilly Manufacturing Plants
Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County.
CivicaScript Launches Low-Cost Generic Dimethyl Fumarate for Multiple Sclerosis Treatment
CivicaScript, a nonprofit company, has launched generic dimethyl fumarate delayed-release capsules for multiple sclerosis treatment at $47 per bottle to pharmacies, with a maximum retail price of $68.
California's State-Branded Insulin Program Faces Significant Delays, No Clear Launch Timeline
• California's ambitious $100-million CalRx insulin initiative, announced two years ago with a promised 2024 delivery, is significantly behind schedule with potential delays extending to 2030. • Civica, Inc., the contracted manufacturer, has not yet begun clinical trials or FDA approval process for the five planned insulin types, though manufacturing has commenced. • The delay impacts over 3.5 million Californians with diabetes, while alternative solutions like insulin price caps have been vetoed by Governor Newsom in favor of the CalRx program.